Monte Rosa Therapeutics EBIT per Share
The EBIT per Share of Monte Rosa Therapeutics (GLUE) as of Oct 9, 2026 is -0.83 USD. In the previous year, EBIT per Share was -1.32 USD — a change of -37.36% (higher).
Get this data via API
Financial Data API
EBIT per Share
-0.83USD
YoY
-37.36%
Last updated:
EBIT per Share of Monte Rosa Therapeutics is 2025 -0.83 USD. EBIT per Share of Monte Rosa Therapeutics was 2024 -1.32 USD. It decreases by -37.36% higher compared to the previous year.
The Monte Rosa Therapeutics EBIT per Share history
3 Years
10 Years
25 Years
Max
EBIT per Share
Date
EBIT per Share
Jan 1, 2023
-2.52 USD
Jan 1, 2024
-1.32 USD
Jan 1, 2025
-0.83 USD
Jan 1, 2026 (e)
-1.27 USD
Jan 1, 2027 (e)
-3.16 USD
Jan 1, 2028 (e)
-2.77 USD
Jan 1, 2029 (e)
-2.24 USD
Jan 1, 2030 (e)
-2.17 USD
| YEAR | EBIT per Share | YoY |
|---|---|---|
| est | -2.17USD | -3.07% |
| est | -2.24USD | -19.14% |
| est | -2.77USD | -12.30% |
| est | -3.16USD | +149.28% |
| est | -1.27USD | +53.08% |
| -0.83USD | -37.36% | |
| -1.32USD | -47.56% | |
| -2.52USD | +9.52% | |
| -2.30USD | +45.04% | |
| -1.58USD | +22.99% | |
| -1.29USD | +609.27% | |
| -0.18USD | — |
Access this data via the Eulerpool API
Monte Rosa Therapeutics Stock analysis
What does Monte Rosa Therapeutics do? Monte Rosa Therapeutics is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Monte Rosa Therapeutics stock
EBIT per Share of Monte Rosa Therapeutics is -0.83 USD in 2025.
EBIT per Share of Monte Rosa Therapeutics changed from -1.32 USD to -0.83 USD, representing a -37.36% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of EBIT per Share Monte Rosa Therapeutics since 2006 – with annual values, charts, and detailed analysis.
EBIT per Share measures operating profit allocated to each outstanding share.
Access this data via the Eulerpool API
Income Statement — Monte Rosa Therapeutics
All Key Metrics — Monte Rosa Therapeutics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth